<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337194</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02822</org_study_id>
    <secondary_id>NCI-2012-02822</secondary_id>
    <secondary_id>CALGB-50502</secondary_id>
    <secondary_id>CALGB-50502</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>P30CA014236</secondary_id>
    <nct_id>NCT00337194</nct_id>
  </id_info>
  <brief_title>SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma</brief_title>
  <official_title>A Randomized Double-Blinded Placebo Controlled Phase II Study of the Anti-CD30 Antibody, SGN-30 (NSC #731636), in Combination With Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD) for Patients With Relapsed/Refractory Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies the side effects and how well giving monoclonal
      antibody SGN-30 together with combination chemotherapy works in treating patients with
      Hodgkin lymphoma that has returned after a period of improvement or did not respond to
      previous treatment. Monoclonal antibodies, such as SGN-30, may interfere with the ability of
      cancer cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine
      hydrochloride, vinorelbine tartrate, and pegylated liposomal doxorubicin hydrochloride, work
      in different ways to stop the growth of cancer cells, either by killing the cells or by
      stopping them from dividing. Giving monoclonal antibody SGN-30 together with combination
      chemotherapy may kill more cancer cells and shrink tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the complete and partial response rates following treatment with the
      anti-cluster of differentiation (CD) 30 antibody, SGN-30 (monoclonal antibody SGN-30), and
      gemcitabine (gemcitabine hydrochloride), vinorelbine (vinorelbine tartrate), and pegylated
      liposomal doxorubicin (pegylated liposomal doxorubicin hydrochloride) (GVD) in patients with
      relapsed or refractory Hodgkin lymphoma (HL).

      II. To assess time to progression and overall survival in patients treated with SGN-30 and
      GVD in patients with relapsed or refractory Hodgkin lymphoma (HL).

      III. To evaluate the toxicity of SGN-30 in combination with GVD in patients with relapsed and
      refractory HL.

      SECONDARY OBJECTIVES:

      I. To determine the pharmacokinetic profile of SGN-30 when combined with GVD chemotherapy.

      II. To correlate soluble (s) CD30 levels with response to treatment. III. To determine the
      incidence of human anti-chimeric antibodies (HACA) formation following repetitive SGN-30
      dosing.

      IV. To correlate Fc gamma receptor polymorphisms with response to treatment.

      OUTLINE:

      Part 1 (closed to accrual as of 5/18/2007): Patients receive monoclonal antibody SGN-30
      intravenously (IV) over 2 hours, vinorelbine tartrate IV over 6-10 minutes, gemcitabine
      hydrochloride IV over 30 minutes, and pegylated doxorubicin hydrochloride liposome IV over 90
      minutes on days 1 and 8. Treatment repeats every 21 days until 10 out of 16 patients complete
      1 course in the absence of unacceptable toxicity. Subsequent patients receive treatment on
      part 2.

      Part 2: Patients are randomized to 1 of 2 treatment arms.

      Arm I: Patients receive monoclonal antibody SGN-30 IV over 2 hours, vinorelbine tartrate IV
      over 6-10 minutes, gemcitabine hydrochloride IV over 30 minutes, and pegylated doxorubicin
      hydrochloride liposome IV over 90 minutes on days 1 and 8.

      Arm II (closed to accrual as of 12/4/07): Patients receive placebo IV over 2 hours,
      vinorelbine tartrate IV over 6-10 minutes, gemcitabine hydrochloride IV over 30 minutes, and
      pegylated doxorubicin hydrochloride liposome IV over 90 minutes on days 1 and 8.

      Treatment in both arms repeats every 21 days for up to 6 courses in the absence of disease
      progression or unacceptable toxicity.

      NOTE: Treatment with SGN-30/placebo was stopped on 4/12/2007 due to pulmonary toxicity.

      After completion of study treatment, patients are followed up periodically for up to 10
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Overall Response (OR)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>The number of participants who respond (complete or partial) to treatment. Response was defined using the revised criteria for malignant lymphoma. Complete response (CR): complete disappearance of all detectable disease; partial response (PR): &gt;= 50% reduction in sum of the product of diameters of indicator lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Event free survival is the time from trial entry until progression, death, or termination of treatment due to nonresponse. Patients who went on to receive a stem cell transplant (SCT) were not censored from the EFS survival at the time of transplant and were only considered failures at the time of relapse or death from any cause. The median EFS with 95% confidence interval (CI) was estimated using the Kaplan Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) At 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients who were alive at 1 year. The 1-year survival rate was estimated using the Kaplan Meier method.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak Serum Level of Monoclonal Antibody SGN-30</measure>
    <time_frame>Up to day 21 of course 6</time_frame>
    <description>Record the highest serum level of monoclonal antibody SGN-30 achieved.</description>
  </other_outcome>
  <other_outcome>
    <measure>sCD30 Levels</measure>
    <time_frame>Up to day 21 of course 6</time_frame>
    <description>A 2-sided t-test with alpha = 0.05 will be used to compare sCD30 levels between responders (OR) and non-responders groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fc Gamma Receptor Polymorphisms</measure>
    <time_frame>Baseline</time_frame>
    <description>Fisher's exact test with 2-sided alpha = 0.05 will be used to compare the response probabilities in patients with V/V (valine expression), V/F (heterozygous), and F/F (homozygous for phenylalanine) for each of Fc gamma RIIIa a</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Adult Lymphocyte Depletion Hodgkin Lymphoma</condition>
  <condition>Adult Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Adult Mixed Cellularity Hodgkin Lymphoma</condition>
  <condition>Adult Nodular Sclerosis Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (SGN-30, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo, chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody SGN-30</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (SGN-30, chemotherapy)</arm_group_label>
    <other_name>SGN-30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (placebo, chemotherapy)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine tartrate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (SGN-30, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (placebo, chemotherapy)</arm_group_label>
    <other_name>Eunades</other_name>
    <other_name>navelbine ditartrate</other_name>
    <other_name>NVB</other_name>
    <other_name>VNB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (SGN-30, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (placebo, chemotherapy)</arm_group_label>
    <other_name>CAELYX</other_name>
    <other_name>Dox-SL</other_name>
    <other_name>DOXIL</other_name>
    <other_name>doxorubicin hydrochloride liposome</other_name>
    <other_name>LipoDox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (SGN-30, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (placebo, chemotherapy)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (SGN-30, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (placebo, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (SGN-30, chemotherapy)</arm_group_label>
    <arm_group_label>Arm II (placebo, chemotherapy)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented CD30-positive classical Hodgkin lymphoma according to the
             World Health Organization (WHO) classification of lymphoid malignancies that is
             recurrent or refractory after at least one prior therapy

               -  Note: Patients with nodular lymphocyte predominant HL are not eligible; all other
                  subtypes including nodular sclerosis, lymphocyte-depleted, lymphocyte rich, and
                  mixed cellularity HL may be enrolled

               -  Core needle biopsies are acceptable if they contain adequate tissue for primary
                  diagnosis and immunophenotyping; bone marrow biopsies as the sole means of
                  diagnosis are not acceptable, but they may be submitted in conjunction with nodal
                  biopsies; fine needle aspirates are not acceptable; if the original diagnostic
                  specimen is not available, specimens obtained at relapse may be submitted; if
                  multiple specimens are available, please submit the most recent; failure to
                  submit pathology specimens within 60 days of patient registration will be
                  considered a major protocol violation

          -  Patients must have relapsed or refractory disease after at least one prior therapy,
             with at least a 3 week interval from the completion of the most recent chemotherapy or
             radiotherapy regimen; recovery to =&lt; grade 1 from all toxicities related to the prior
             treatments is required; patients who have previously received a stem cell transplant
             are permitted to enroll on this study

               -  Prior treatment with an anti-CD30 antibody, gemcitabine, vinorelbine, or
                  pegylated liposomal doxorubicin is not permitted

          -  No uncontrolled angina, no myocardial infarction (MI) within 6 months of study entry,
             and no New York Heart Association (NYHA) class II or greater congestive heart failure
             (CHF)

          -  Baseline left ventricular ejection fraction (LVEF) by multi gated acquisition scan
             (MUGA) or echocardiogram (ECHO) must be &gt;= 45%

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Measurable disease must be present on either physical examination or imaging studies;
             evaluable or non-measurable disease alone is not acceptable

               -  Measurable disease is defined as any lesion that can be accurately measured in at
                  least one dimension (longest diameter to be recorded) as &gt;= 10 mm

               -  Non-measurable disease includes all other lesions, including small lesions (&lt; 10
                  mm) and truly non-measurable lesions

               -  Lesions that are considered non-measurable include the following:

                    -  Bone lesions (lesions, if present, should be noted)

                    -  Bone marrow involvement (if present, this should be noted)

                    -  Ascites

                    -  Pleural/pericardial effusion

                    -  Lymphangitis cutis/pulmonis

          -  Pregnant or nursing women may not be enrolled; women of childbearing potential must
             have a negative serum or urine pregnancy test prior to registration; women and men of
             reproductive potential should agree to use an effective means of birth control

          -  Corrected diffusion capacity of carbon monoxide (DLCO) &gt;= 50%

          -  Absolute neutrophil count (ANC) &gt;= 1,200/uL

          -  Platelet count &gt;= 100,000/uL

          -  Creatinine =&lt; 2.0 mg/dL

          -  Bilirubin =&lt; 2.0 mg/dL

               -  Absent a history of Gilbert's disease

          -  Aspartate aminotransferase (AST) =&lt; 2.0 x upper limits of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristie Blum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2006</study_first_submitted>
  <study_first_submitted_qc>June 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2006</study_first_posted>
  <results_first_submitted>February 10, 2015</results_first_submitted>
  <results_first_submitted_qc>February 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From April 2006 to December 2007 10 institutions recruited 30 participants to this trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (SGN-30, Chemotherapy)</title>
          <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
monoclonal antibody SGN-30: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Placebo, Chemotherapy)</title>
          <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
placebo: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subsequent non-protocol therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (SGN-30, Chemotherapy)</title>
          <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
monoclonal antibody SGN-30: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Placebo, Chemotherapy)</title>
          <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
placebo: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="19" upper_limit="78"/>
                    <measurement group_id="B2" value="38" lower_limit="25" upper_limit="53"/>
                    <measurement group_id="B3" value="35" lower_limit="19" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior autologous transplant</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Overall Response (OR)</title>
        <description>The number of participants who respond (complete or partial) to treatment. Response was defined using the revised criteria for malignant lymphoma. Complete response (CR): complete disappearance of all detectable disease; partial response (PR): &gt;= 50% reduction in sum of the product of diameters of indicator lesions.</description>
        <time_frame>Up to 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (SGN-30, Chemotherapy)</title>
            <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
monoclonal antibody SGN-30: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo, Chemotherapy)</title>
            <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
placebo: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Response (OR)</title>
          <description>The number of participants who respond (complete or partial) to treatment. Response was defined using the revised criteria for malignant lymphoma. Complete response (CR): complete disappearance of all detectable disease; partial response (PR): &gt;= 50% reduction in sum of the product of diameters of indicator lesions.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Free Survival (EFS)</title>
        <description>Event free survival is the time from trial entry until progression, death, or termination of treatment due to nonresponse. Patients who went on to receive a stem cell transplant (SCT) were not censored from the EFS survival at the time of transplant and were only considered failures at the time of relapse or death from any cause. The median EFS with 95% confidence interval (CI) was estimated using the Kaplan Meier method.</description>
        <time_frame>Up to 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (SGN-30, Chemotherapy)</title>
            <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
monoclonal antibody SGN-30: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo, Chemotherapy)</title>
            <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
placebo: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Event Free Survival (EFS)</title>
          <description>Event free survival is the time from trial entry until progression, death, or termination of treatment due to nonresponse. Patients who went on to receive a stem cell transplant (SCT) were not censored from the EFS survival at the time of transplant and were only considered failures at the time of relapse or death from any cause. The median EFS with 95% confidence interval (CI) was estimated using the Kaplan Meier method.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="4.7">he upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment.</measurement>
                    <measurement group_id="O2" value="4.1" lower_limit="1.8">he upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) At 1 Year</title>
        <description>Percentage of patients who were alive at 1 year. The 1-year survival rate was estimated using the Kaplan Meier method.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (SGN-30, Chemotherapy)</title>
            <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
monoclonal antibody SGN-30: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo, Chemotherapy)</title>
            <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
placebo: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) At 1 Year</title>
          <description>Percentage of patients who were alive at 1 year. The 1-year survival rate was estimated using the Kaplan Meier method.</description>
          <units>percentage of participants</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="61" upper_limit="95"/>
                    <measurement group_id="O2" value="30" lower_limit="13" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Serum Level of Monoclonal Antibody SGN-30</title>
        <description>Record the highest serum level of monoclonal antibody SGN-30 achieved.</description>
        <time_frame>Up to day 21 of course 6</time_frame>
        <population>Data was only available on 10 participants from Arm 1. (No participants from Arm II were evaluable for this endpoint as they did not receive SGN-30 per protocol.)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (SGN-30, Chemotherapy)</title>
            <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
monoclonal antibody SGN-30: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Serum Level of Monoclonal Antibody SGN-30</title>
          <description>Record the highest serum level of monoclonal antibody SGN-30 achieved.</description>
          <population>Data was only available on 10 participants from Arm 1. (No participants from Arm II were evaluable for this endpoint as they did not receive SGN-30 per protocol.)</population>
          <units>mg/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339" lower_limit="141" upper_limit="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>sCD30 Levels</title>
        <description>A 2-sided t-test with alpha = 0.05 will be used to compare sCD30 levels between responders (OR) and non-responders groups.</description>
        <time_frame>Up to day 21 of course 6</time_frame>
        <population>Nine participants submitted pretreatment sCD30 samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Responders</title>
            <description>Subset of patients who achieved an overall response, as describer in primary outcome measure 1.</description>
          </group>
          <group group_id="O2">
            <title>Non-responders</title>
            <description>Subset of patients who did not achieve an overall response, as defined in primary outcome measure 1</description>
          </group>
        </group_list>
        <measure>
          <title>sCD30 Levels</title>
          <description>A 2-sided t-test with alpha = 0.05 will be used to compare sCD30 levels between responders (OR) and non-responders groups.</description>
          <population>Nine participants submitted pretreatment sCD30 samples.</population>
          <units>U/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.2" lower_limit="14.3" upper_limit="1992.0"/>
                    <measurement group_id="O2" value="76.5" lower_limit="21" upper_limit="219.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fc Gamma Receptor Polymorphisms</title>
        <description>Fishers exact test with 2-sided alpha = 0.05 will be used to compare the response probabilities in patients with V/V (valine expression), V/F (heterozygous), and F/F (homozygous for phenylalanine) for each of Fc gamma RIIIa a</description>
        <time_frame>Baseline</time_frame>
        <population>Fc gamma receptor polymorphisms were assessed in 28 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Responders</title>
            <description>Subset of patients who achieved an overall response, as describer in primary outcome measure 1.</description>
          </group>
          <group group_id="O2">
            <title>Non-responders</title>
            <description>Subset of patients who did not achieve an overall response, as defined in primary outcome measure 1</description>
          </group>
        </group_list>
        <measure>
          <title>Fc Gamma Receptor Polymorphisms</title>
          <description>Fishers exact test with 2-sided alpha = 0.05 will be used to compare the response probabilities in patients with V/V (valine expression), V/F (heterozygous), and F/F (homozygous for phenylalanine) for each of Fc gamma RIIIa a</description>
          <population>Fc gamma receptor polymorphisms were assessed in 28 participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V/V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F/V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (SGN-30, Chemotherapy)</title>
          <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
monoclonal antibody SGN-30: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Placebo, Chemotherapy)</title>
          <description>Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
No prior stem cell transplant:
SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 20 mg/m^2 IV days 1 &amp; 8, gemcitabine: 1000 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 &amp; 8.
Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 &amp; 8, vinorelbine: 15 mg/m^2 IV days 1 &amp; 8, gemcitabine: 800 mg/m^2 IV days 1 &amp; 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 &amp; 8.
placebo: Given IV
vinorelbine tartrate: Given IV
pegylated liposomal doxorubicin hydrochloride: Given IV
gemcitabine hydrochloride: Given IV
laboratory biomarker analysis: Correlative studies
pharma</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Visceral edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum magnesium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Body odor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 6</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint- Late RT Morbidity Scoring</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Visceral edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper aerodigestive tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="32" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Laryngeal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kristie Blum</name_or_title>
      <organization>The Ohio State University</organization>
      <email>kristie.blum@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

